TMJ implant oversight
This article was originally published in The Gray Sheet
Executive Summary
Government Accountability Office finds imperfect post-approval reporting by the three firms with approved implants for temporomandibular joint (TMJ) replacement. TMJ Concepts did not submit five of seven required annual reports between 2000 and 2006; and insufficient information was included in six annual reports from TMJ Implants and one report from Walter Lorenz. While FDA sent deficiency letters to the latter two firms, it was not until GAO's investigation, between October 2006 and August 2007, that FDA asked for the missing reports from TMJ Concepts. The 1GAO study was requested by Sens. Edward Kennedy, D-Mass., Tom Harkin, D-Iowa, and Herb Kohl, D-Wis., and released Oct. 17. It examined FDA's oversight, including premarket concerns and monitoring of sponsor compliance with conditions of approval, for the four TMJ implant devices approved since 1998. All the implants required three-year postmarket studies
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.